0001140361-18-006391.txt : 20180209
0001140361-18-006391.hdr.sgml : 20180209
20180209180132
ACCESSION NUMBER: 0001140361-18-006391
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180207
FILED AS OF DATE: 20180209
DATE AS OF CHANGE: 20180209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AYERS JONATHAN W
CENTRAL INDEX KEY: 0001184149
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19271
FILM NUMBER: 18593273
MAIL ADDRESS:
STREET 1: IDEXX LABORATORIES, INC.
STREET 2: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEXX LABORATORIES INC /DE
CENTRAL INDEX KEY: 0000874716
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 010393723
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092-2041
BUSINESS PHONE: 2075560300
MAIL ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092-2041
FORMER COMPANY:
FORMER CONFORMED NAME: IDEXX CORP / DE
DATE OF NAME CHANGE: 19600201
4
1
doc1.xml
FORM 4
X0306
4
2018-02-07
0
0000874716
IDEXX LABORATORIES INC /DE
IDXX
0001184149
AYERS JONATHAN W
ONE IDEXX DRIVE
WESTBROOK
ME
04092
1
1
0
0
Chairman, President & CEO
Common Stock
2018-02-07
4
M
0
18000
38.795
A
1077112
D
Common Stock
2018-02-07
4
S
0
11205
177.6335
D
1065907
D
Common Stock
2018-02-07
4
S
0
4912
178.3556
D
1060995
D
Common Stock
2018-02-07
4
S
0
1883
179.2670
D
1059112
D
Common Stock
2018-02-08
4
M
0
4000
38.795
A
1063112
D
Common Stock
2018-02-08
4
S
0
4000
175.3392
D
1059112
D
Common Stock
98000
I
by Ayers Family Trust
Non-Qualified Stock Option (right-to-buy)
38.795
2018-02-07
4
M
0
18000
D
2018-02-13
Common Stock
18000
4000
D
Non-Qualified Stock Option (right-to-buy)
38.795
2018-02-08
4
M
0
4000
D
2018-02-13
Common Stock
4000
0
D
Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sales price of the shares sold ranging from a low of $177.01 to a high of $178.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Represents the weighted average sales price of the shares sold ranging from a low of $178.0101 to a high of $178.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Represents the weighted average sales price of the shares sold ranging from a low of $179.06 to a high of $179.58 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Represents the weighted average sales price of the shares sold ranging from a low of $175.0201 to a high of $176.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Not applicable.
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan W. Ayers
2018-02-09